Drug intelligence / Profile preview

giredestrant + triptorelin

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

Giredestrant + triptorelin is a combination therapy consisting of an oral selective estrogen receptor degrader (SERD) and a luteinizing hormone-releasing hormone (LHRH) agonist. Giredestrant works by degrading estrogen receptors, effectively blocking estrogen signaling in breast cancer cells, while triptorelin suppresses ovarian function in premenopausal women, reducing estrogen production. This combination is being investigated primarily for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer in premenopausal women.

Targets

ESR1 (ERα)ESR2 (ERβ)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on giredestrant + triptorelin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on giredestrant + triptorelin.

Explore the full profile